Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Quoin Pharmaceuticals (QNRX): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 6, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow QNRX for free
Share

Sections with a free account

1 concentrated manager holds it with a median weight of 0.0%.

Who owns Quoin Pharmaceuticals?

Quoin Pharmaceuticals trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Stonepine Capital Management, 10.0% (13G/A filed May 15, 2026), Resolute Capital Asset Partners, 8.5% (13G filed Dec 11, 2025) and Integrated Core Strategies (US), 5.5% (13G filed Jun 2, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were Dauntless Investment Group (214,987 ADRs), Ikarian Capital (211,538 ADRs) and Stonepine Capital Management (199,486 ADRs).

Which institutions hold the most Quoin Pharmaceuticals shares?

Per Form 13F filings as of Jun 30, 2026, in ADRs:

  1. 1. Dauntless Investment Group: 214,987 ADRs
  2. 2. Ikarian Capital: 211,538 ADRs
  3. 3. Stonepine Capital Management: 199,486 ADRs
  4. 4. Millennium Management: 112,323 ADRs
  5. 5. SummitTX Capital: 100,300 ADRs
  6. 6. Woodline Partners: 76,446 ADRs
  7. 7. Aberdeen Group: 75,000 ADRs
  8. 8. Soleus Capital Management: 72,730 ADRs
  9. 9. AIGH Capital Management: 70,000 ADRs
  10. 10. Boothbay Fund Management: 59,838 ADRs

Sources:13G/A by Stonepine Capital Management (May 15, 2026) ↗13G by Resolute Capital Asset Partners (Dec 11, 2025) ↗13G by Integrated Core Strategies (US) (Jun 2, 2026) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Concentrated managers
1
All 13F: 19
Consensus
—
No score: it needs 5 or more concentrated managers
Price at Jun 30, 2026 (per 13F)
$4.84
-26.7% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (1 → 1): 0 opened · 0 exited = 0

Net flow in the quarter: $0K (0 shares) · bought $0 and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of QNRX (all 13F filers)

  • Dauntless Investment Group215 KType not verified · 0.31% of the company+18 K
  • Ikarian Capital212 KType not verified · 0.30% of the company0
  • Stonepine Capital Management199 KInvestment firm · 0.28% of the company+146 K
  • Millennium Management112 KQuant or multi-manager · 0.16% of the company+36 K
  • SummitTX Capital100 KType not verified · 0.14% of the company0
  • Woodline Partners76 KInvestment firm · 0.11% of the company−3,136
  • Aberdeen Group75 KInvestment firm · 0.11% of the company0
  • Soleus Capital Managementconcentrated73 KInvestment firm · 0.10% of the company0
  • AIGH Capital Management70 KType not verified · 0.10% of the company+19 K
  • Boothbay Fund Management60 KType not verified · 0.09% of the company0

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Fundamentals

12-month figures to Jun 30, 2026 · balance sheet as of Jun 30, 2026.

Profitability
Operating margin
—
Net margin
—
ROE
—
Growth
Revenue (TTM)
—
Revenue growth
—
Net income (TTM)
$-18.7M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
—
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income
Debt due within 12 months
no data

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
0
Amount (6 m)
$0
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • Ikarian Capital4.4%(fell below 5%)13G · amendmentfiling ↗Event: Sep 30, 2026 · filed: Oct 7, 2026
  • Integrated Core Strategies (US)5.5%13Gfiling ↗Event: May 26, 2026 · filed: Jun 2, 2026
  • ADAR1 Capital Management4.9%(fell below 5%)13G · amendmentfiling ↗Event: Mar 31, 2026 · filed: May 15, 2026

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Aug 28, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

  • Aug 20, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Nov 17, 2025Routinefiling ↗

    Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow QNRX for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow QNRX